Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Patel Chem Specialities IPO
Patel Chem Specialities Ltd
₹1,31,200 /1600 sharesMinimum Investment
Patel Chem Specialities IPO Listing Details
| Listed On | Issue Price | Listing Price | Listing Gains |
|---|---|---|---|
| -- | ₹84.00 | ₹110.00 | ₹26.00 (30.95%) |
Patel Chem Specialities IPO Details
| Bidding Dates | Min. Investment | Lot Size | Price Range |
|---|---|---|---|
| 25 Jul ‘25 - 29 Jul ‘25 | ₹2,62,400 | 1,600 | ₹82 - ₹84 |
| Issue Size | IPO Doc |
|---|---|
| 58.80Cr | RHP PDF |
Subscription rate
As of 29 Jul'25, 04:00 PM
| Qualified Institutional Buyers | 93.81x |
| Non-Institutional Investor | 235.68x |
| Retail Individual Investor | 166.53x |
| Total | 106.89x |
About Patel Chem Specialities
Founded in
2008
Managing director
Mr. Bhupesh Patel
Parent organisation
Patel Chem Specialities Ltd
Strengths & Financials of Patel Chem Specialities
Strengths
Risks
The company claims that it has built a strong international presence by exporting its products to over 15 countries, including the United States (US), Germany, the United Kingdom (UK), Japan, China, and Australia.
The company is ISO 9001:2015 certified for its quality management systems. The company also claims to hold certifications such as hazard analysis and critical control points (HAACP), Kosher, Halal, and Food Safety and Standards Authority of India (FSSAI).
As of FY25, the company claimed to have served more than 350 customers across various industrial sectors, including dealers and agents around the world.
According to the RHP, the company lays emphasis on research and development (R&D) and its R&D facility, located at the Vatva unit, is equipped with advanced chemical and analytical labs.
For exports, the company claims that it complies with the quality standards set by several pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (EP), British Pharmacopoeia (BP), Japanese Pharmacopoeia (JP), and Indian Pharmacopoeia (IP). A dedicated Quality Division manages these standards through regular Standard Operating Procedures (SOPs) and Standard Test Procedures (STPs) on both raw materials and final products.
Over the years, the company has observed a consistent increase in its revenue from operations and profit after tax (PAT). Revenue from operations increased from Rs 69.40 crore in FY23 to Rs 82.36 crore in FY24 and Rs 105.09 crore in FY25. PAT increased from Rs 2.89 crore in FY23 to Rs 7.66 crore in FY24 and Rs 10.56 crore in FY25.
The top five suppliers accounted for Rs 33.59 crore (43.97 percent) of the company’s purchases in FY25, Rs 29.69 crore (49.41 percent) in FY24, and Rs 28.40 crore (47.51 percent) in FY22. Furthermore, the top supplier alone accounted for Rs 17.53 crore (22.95 percent) of the company’s total purchases in FY25, Rs 14.48 crore (24.10 percent) in FY24, and Rs 13.89 crore (23.24 percent) in FY23. Any disruption in supplies from one or more of these could adversely affect the company’s business and finances.
The company relies heavily on three states, Gujarat, Maharashtra, and Delhi, for its domestic purchases. They accounted for 94.34 percent, 95.43 percent, and 92.33 percent of the company’s total domestic purchases in FY25, FY24, and FY23, respectively. Any interruption in supply from these regions could negatively impact the company’s ability to source raw materials on time, thereby adversely affecting its operations.
The company relies heavily on imports from China. It accounted for 34.58 percent, 30.42 percent, and 32.89 percent of the company’s total purchases in FY25, FY24, and FY23, respectively. Any disruption in the supply chain from China could adversely affect the company’s ability to procure essential raw materials, leading to delays in production, increased costs, and potential loss of business.
The company derives a significant portion of its revenue from Gujarat, Maharashtra, and West Bengal. These three states accounted for 65.97 percent of the company’s total domestic sales in FY25, 60.74 percent in FY24, and 64.72 percent in FY23. Any decline in sales from any of these regions could negatively impact revenue and profit.
A significant portion of the company’s export sales is derived from Egypt, the US, Russia, South Korea, the UK, Japan, and Germany. Exports accounted for Rs 11.55 crore (63.93 percent) of the company’s total revenue in FY25, Rs 7.47 crore (65.57 percent) in FY24, and Rs 4.66 crore (66.39 percent) in FY23. Any decline in demand or regulatory challenges in these countries could adversely affect the company’s financial performance.
The company’s revenue is heavily dependent on the performance of the pharmaceutical sector. It accounted for Rs 70.84 crore (67.41 percent) of the company’s total revenue in FY25, Rs 54.12 crore (65.72 percent) in FY24, and Rs 40.25 crore (58.01 percent) in FY23. Any slowdown or negative developments in this industry could impact the company's financial performance.
The company recorded negative cash flows from investing activities amounting to Rs 7.20 crore in FY25, Rs 5.94 crore in FY24, and Rs 3.27 crore in FY23. Additionally, the company reported a net decrease in cash and cash equivalents amounting to Rs 0.50 crore in FY23. If cash outflows continue to exceed inflows, the company may face liquidity challenges in the future.
The company, its promoters, directors, and group entities are involved in certain legal proceedings. Any adverse judgments in any of these cases could be detrimental to the company’s business prospects.
Patel Chem Specialities Financials
*All values are in Rs. Cr
No Graph Data To Display
Application Details of Patel Chem Specialities IPO
| Apply as | Price band | Apply Range |
|---|---|---|
| Regular | ₹82 - 84 | ₹2 - 5 Lakh |
| High Networth Individual | ₹82 - 84 | ₹2 - 5 Lakh |
For Patel Chem Specialities IPO, eligible investors can apply as Regular.